// App-Quantinova.ai

1026 : A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).

Researchers

Presenter

  • Jose Pablo Leone

Principal Investigators

  • Jiani Hu

  • William Thomas Barry

  • Dan G. Duda

  • Elizabeth Robins Gerstner

  • Rakesh K. Jain

  • Sally Tan

  • Elizabeth S Lawler

  • Eric P. Winer

  • Nancy U. Lin

  • Sara M. Tolaney

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Cabozantinib

  • Trastuzumab

Outcome

  • N/A

Study Design

  • Single Arm

  • Cohort

Phase

  • II

Study Id's

  • NCT02260531

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved